Seeking Alpha

Sarepta Therapeutics (SRPT) soars 114% premarket after the company announces its eteplirsen...

Sarepta Therapeutics (SRPT) soars 114% premarket after the company announces its eteplirsen treatment for Duchenne muscular dystrophy met its primary endpoint in a Phase IIb study. (PR)
Comments (1)
  • SA Editor Eli Hoffmann
    , contributor
    Comments (818) | Send Message
     
    Wow - kudos to R.S analytics (http://bit.ly/Qr046k) and Sean Anderson (http://bit.ly/QOEPh9) for one great call!

     

    And, more importantly, huge news for DMD kids!
    3 Oct 2012, 08:02 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs